You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Axogen, Inc. said it will move forward with a prostate market launch, citing a $754m TAM and Avance® data in >220 reconstructed patients, including ~80% with better than expected erectile function and >95% with return of continence at 6 months.
Axogen reported third-quarter 2026 revenue of $75.8 million, up 26.2%, adjusted EBITDA $13.4 million, and raised full-year revenue guidance to at least $290 million. It completed BioCircuit acquisition October 1st and plans prostate market development 2027.
Axogen reported third-quarter revenue of $75,834, up 26.2%, and net income of $2,334, but nine-month net loss reached $18,766. Cash and investments totaled $348,068 as of September 30, 2026, and Axogen completed the BioCircuit acquisition on October 1, 2026.
Axogen reported third-quarter revenue of $75.8 million, up 26.2%, adjusted net income of $13.1 million and raised full-year guidance to at least $290 million, including at least $7 million from the BioCircuit acquisition completed October 1, 2026.
Axogen completed its acquisition of BioCircuit Technologies. BioCircuit is expected to contribute approximately $6 million in fourth-quarter 2026 and approximately $34 million in 2027 revenue, not included in Axogen’s full-year 2026 guidance of at least 24% revenue growth.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Axogen reported Q2 revenue of $69.7M, up 23.1% YoY, and raised full-year 2026 revenue growth guidance to at least 24% (≥$279M), while lowering full-year gross margin guidance to at least 73% due to unfavorable breast-related product mix.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AXGN
this stock
Axogen, Inc.
|
$3.34B | +70.9% | +20.2% | — | 11.7% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Axogen, Inc. said it will move forward with a prostate market launch, citing a $754m TAM and Avance® data in >220 reconstructed patients, including ~80% with better than expected erectile function and >95% with return of continence at 6 months.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AXGN | +11.8% | +61.6% | +34.9% | +13.3% | +70.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +9.2% | +62.7% | +34.4% | +13.5% | +60.3% |
